# Profound Medical

Type: Company (PROF)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/profound-medical
Canonical HTML page: https://getfinancebrief.com/entity/profound-medical

## Timeline

- **2026-Q4 (estimated)**: PROF Break-even — Target window for Profound Medical to reach cash-flow neutrality.
- **2026-Q2 (estimated)**: Kura NDA Submission — Anticipated filing for ziftomenib with the FDA.
- **2026-03-05**: Q4 Earnings Release — Both companies report pivotal year-end results.
- **2025-01-01**: CPT Code Activation — Category 1 CPT codes for TULSA-PRO go live in the U.S.

## Recent coverage (2 stories)

### Kura and Profound Signal Commercial Inflection Points in Q4 Results
2026-03-06 05:18:01 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a pivotal shift toward commercial execution. Kura is nearing an NDA submission for its lead leukemia candidate, while Profound saw record revenue growth following the first full year of Category 1 CPT code implementation.
Full story: https://getfinancebrief.com/story/kura-oncology-profound-medical-q4-earnings-analysis-2026

### Rumble and Mid-Cap Tech Leaders Report Q4 2025 Earnings Amid Sector Shifts
2026-03-05 22:46:11 · Sentiment: Neutral · Impact: 5/10 · Sources: 5

A cluster of mid-cap and small-cap companies, led by Rumble and Atea Pharmaceuticals, released fourth-quarter and full-year 2025 results, signaling a period of strategic transition. The reports highlight a divergence between high-growth digital infrastructure and the clinical-stage healthcare sector as firms navigate the post-2024 economic landscape.
Full story: https://getfinancebrief.com/story/rumble-atea-profound-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.